Clinical trial design and management

Research output: Contribution to journalArticle

Abstract

The randomised, controlled trial (RTC) is considered the gold standard for the assessment of the effect of any therapeutic intervention. However, rare diseases carry several issues in terms of population size, life-threatening nature of the condition and lack of other available treatments, which basically render this approach not always feasible. Alternative methodological approaches are being developed to better suit the need of an orphan drug development.

Original languageEnglish
Pages (from-to)57-62
Number of pages6
JournalPharmaceuticals Policy and Law
Volume12
Issue number1-2
DOIs
Publication statusPublished - 2010

Fingerprint

Orphan Drug Production
Therapeutic Uses
Rare Diseases
Population Density
Randomized Controlled Trials
Clinical Trials

Keywords

  • controlled trial
  • population size
  • Randomised
  • rare disorder

ASJC Scopus subject areas

  • Health Policy
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

Clinical trial design and management. / Baiardi, Paola; Santilli, Veronica.

In: Pharmaceuticals Policy and Law, Vol. 12, No. 1-2, 2010, p. 57-62.

Research output: Contribution to journalArticle

@article{0a3aa6083e404746a76743d6ff6d2ea7,
title = "Clinical trial design and management",
abstract = "The randomised, controlled trial (RTC) is considered the gold standard for the assessment of the effect of any therapeutic intervention. However, rare diseases carry several issues in terms of population size, life-threatening nature of the condition and lack of other available treatments, which basically render this approach not always feasible. Alternative methodological approaches are being developed to better suit the need of an orphan drug development.",
keywords = "controlled trial, population size, Randomised, rare disorder",
author = "Paola Baiardi and Veronica Santilli",
year = "2010",
doi = "10.3233/PPL-2010-0267",
language = "English",
volume = "12",
pages = "57--62",
journal = "Pharmaceuticals Policy and Law",
issn = "1389-2827",
publisher = "IOS Press",
number = "1-2",

}

TY - JOUR

T1 - Clinical trial design and management

AU - Baiardi, Paola

AU - Santilli, Veronica

PY - 2010

Y1 - 2010

N2 - The randomised, controlled trial (RTC) is considered the gold standard for the assessment of the effect of any therapeutic intervention. However, rare diseases carry several issues in terms of population size, life-threatening nature of the condition and lack of other available treatments, which basically render this approach not always feasible. Alternative methodological approaches are being developed to better suit the need of an orphan drug development.

AB - The randomised, controlled trial (RTC) is considered the gold standard for the assessment of the effect of any therapeutic intervention. However, rare diseases carry several issues in terms of population size, life-threatening nature of the condition and lack of other available treatments, which basically render this approach not always feasible. Alternative methodological approaches are being developed to better suit the need of an orphan drug development.

KW - controlled trial

KW - population size

KW - Randomised

KW - rare disorder

UR - http://www.scopus.com/inward/record.url?scp=78049387800&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78049387800&partnerID=8YFLogxK

U2 - 10.3233/PPL-2010-0267

DO - 10.3233/PPL-2010-0267

M3 - Article

AN - SCOPUS:78049387800

VL - 12

SP - 57

EP - 62

JO - Pharmaceuticals Policy and Law

JF - Pharmaceuticals Policy and Law

SN - 1389-2827

IS - 1-2

ER -